Reaction
Chorioretinopathy reporting signals
As of the last recalculation, Chorioretinopathy appears in 1,422 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is VEMURAFENIB (PRR 54.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Vemurafenib | 43 | 54.0 | 54.2 |
| Trametinib | 51 | 32.0 | 32.1 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 46 | 29.7 | 29.7 |
| Dabrafenib | 41 | 29.3 | 29.4 |
| Methylprednisolone Acetate | 13 | 24.0 | 24.0 |
| Triamcinolone Acetonide | 47 | 23.0 | 23.0 |
| Encorafenib | 13 | 19.4 | 19.4 |
| Prednisolone | 190 | 17.6 | 17.7 |
| Prednisolone Oral | 190 | 17.6 | 17.7 |
| Prednisolone Oral Solution | 190 | 17.6 | 17.7 |
| Azelastine | 13 | 10.7 | 10.7 |
| Sildenafil | 41 | 10.6 | 10.6 |
| Eplerenone | 9 | 10.3 | 10.4 |
| Sildenafil Powder, | 24 | 10.0 | 10.0 |
| Clobetasol Propionate | 6 | 8.5 | 8.5 |
| Ranibizumab | 15 | 8.3 | 8.4 |
| Sildenafil Citrate | 65 | 7.8 | 7.8 |
| Remdesivir | 7 | 7.7 | 7.7 |
| Minoxidil Foam 5% (Womens) | 10 | 4.5 | 4.5 |
| Minoxidil | 10 | 3.3 | 3.3 |
| Aflibercept | 6 | 2.8 | 2.8 |